Evidence map›Paper›PMID 33163336›Full record

ReviewActa pharmaceutica Sinica. B2020

Recent advances in screening active components from natural products based on bioaffinity techniques.

Xiaofang Hou, Meng Sun, Tao Bao, Xiaoyu Xie, Fen Wei, Sicen Wang

Abstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Potent inhibition of human tyrosinase inhibitor by verproside from the whole plant ofJournal of enzyme inhibition and medicinal chemistry · 2023
    Article
  16. Dissecting the structural heterogeneity of proteins by native mass spectrometry.Protein science : a publication of the Protein Society · 2023
    Review
  17. Article
  18. Acta pharmaceutica Sinica. B · 2022
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaofang HouSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Meng SunCollege of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an 712046, China.
Tao BaoSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Xiaoyu XieSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Fen WeiSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Sicen WangSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural products have provided numerous lead compounds for drug discovery. However, the traditional analytical methods cannot detect most of these active components, especially at their usual low concentrations, from complex natural products. Herein, we reviewed the recent technological advances (2015-2019) related to the separation and screening bioactive components from natural resources, especially the emerging screening methods based on the bioaffinity techniques, including biological chromatography, affinity electrophoresis, affinity mass spectroscopy, and the latest magnetic and optical methods. These screening methods are uniquely advanced compared to other traditional methods, and they can fish out the active components from complex natural products because of the affinity between target and components, without tedious separation works. Therefore, these new tools can reduce the time and cost of the drug discovery process and accelerate the development of more effective and better-targeted therapeutic agents.

Indexed as

AAs, amaryllidaceous alkaloidsABCA1, ATP-binding cassette transporter A1ACE, affinity capillary electrophoresisActive componentsAPTES, 3-aminopropyl-triethoxysilaneASMS, affinity selection mass spectrometryBioaffinity techniquesChE, cholesterol effluxCMC, Cell membrane chromatographyCMMCNTs, Cell membrane magnetic carbon nanotubeCMSP, Cell membrane stationary phaseCNT, carbon nanotubesEGFR, epidermal growth factor receptorFe3O4–NH2, aminated magnetic nanoparticlesFP, fluorescence polarizationHCS, high content screenHTS, high throughout screenHUVEC, human umbilical vein endothelial cellsIMER, immobilized enzyme microreactorMAO-B, monoamine oxidases BMNP, immobilized on nanoparticlesMPTS, 3-mercaptopropyl-trimethoxysilaneMS, mass spectrometryMSPE, magnetic solid-phase extractionNatural productsPD, Parkinson's diseasePMG, physcion-8-O-β-d-monoglucosideRGD, arginine-glycine-aspartic acidScreeningSPR, surface plasmon resonanceSTAT3, signal transducer and activator of transcription 3TCMs, traditional Chinese medicinesTopo I, topoisomerase ITYR-MNPs, tyrosinase-immobilized magnetic nanoparticlesTYR, tyrosinaseUF, affinity ultrafiltrationXOD, xanthine oxidaseα1A-AR, α1A-adrenergic receptor

Identifiers

PMID33163336
PMCPMC7606101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.